Drug and materials development software provider Schrödinger has capped a successful initial public offering at more than $232m.

Schrödinger, the US-based life sciences platform developer backed by internet and technology conglomerate Alphabet and pharmaceutical firm Wuxi AppTec, closed its initial public offering at more than $232m yesterday.

The company floated last week, issuing nearly 11.9 million shares on the Nasdaq Global Market priced at $17.00 each. Its shares closed at $28.64 on their first day of trading and are at $28.61 at time of publication.

Underwriters Morgan Stanley, BofA Securities, Jefferies and BMO Capital Markets Corp subsequently…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Robert Lavine

Robert Lavine is special features editor for Global Venturing.
Email LinkedIn